Skip to main content

Table 1 Patient characteristics

From: Secondary endpoints analysis in patients with estrogen receptor-positive metastatic breast cancer treated with everolimus and exemestane enrolled in Oral Care-BC

  POC Group (n = 82) C Group (n = 87) P-value
n % 95%CI n % 95%CI
Age (years)        0.93
  <  65 42 51.2 (39.9, 62.4) 44 50.6 (39.6, 61.5)  
  ≥ 65 40 48.8 (37.6, 60.1) 43 49.4 (38.5, 60.4)  
BMA        0.84
 Not used 39 47.6 (36.4, 58.9) 40 46.0 (35.2, 57.0)  
 Used 43 52.4 (41.1, 63.6) 47 54.0 (43.0, 64.8)  
Chemotherapy        0.55
 Not used 74 90.2 (81.7, 95.7) 76 87.4 (78.5, 93.5)  
 Used 8 9.8 (4.3, 18.3) 11 12.6 (6.5, 21.5)  
BMI (mg/m2)        0.07
  < 25 54 65.9 (54.6, 76.0) 66 75.9 (65.5, 84.4)  
  ≥ 25 24 29.3 (19.7, 40.4) 21 24.1 (15.6, 34.5)  
 Missing 4 4.9 (1.3, 12.0) 0 0.0 (0.0, 4.2)  
PgR        0.35
 - 12 14.6 (7.8, 24.2) 13 14.9 (8.2, 24.2)  
 + 65 79.3 (68.9, 87.4) 72 82.8 (73.2, 90.0)  
 Unknown 2 2.4 (0.3, 8.5) 2 2.3 (0.3, 8.1)  
 Missing 3 3.7 (0.3, 10.3) 0 0.0 (0. 4.2)  
Metastatic site        0.07
 Non-visceral 34 41.5 (30.7, 52.9) 28 32.2 (22.6, 43.1)  
 Visceral 45 54.9 (43.5, 65.9) 59 67.8 (56.9, 77.4)  
 Missing 3 3.7 (0.8, 10.3) 0 0.0 (0.0, 4.2)  
Metastatic type        0.07
 De novo 58 70.7 (59.6, 80.3) 72 82.8 (73.2, 90.0)  
 Metastatic 21 25.6 (16.6, 36.4) 15 17.2 (10.0, 26.8)  
 Missing 3 3.7 (0.8, 10.3) 0 0.0 (0.0, 4.2)  
Endocrine therapy for MBC        0.40
 0 13 15.9 (8.7, 25.6) 8 9.2 (4.1, 17.3)  
 1 17 20.7 (12.6, 31.1) 25 28.7 (19.5, 39.4)  
 2 23 28.0 (18.7, 39.1) 27 31.0 (21.5, 41.9)  
 3 29 35.4 (25.1, 46.7) 27 31.0 (21.5, 41.9)  
Incidence of oral mucositis within 8 weeks        0.02
 No 20 24.4 (15.6, 35.1) 9 10.3 (4.8, 18.7)  
 Yes 62 75.6 (64.9, 84.4) 78 89.7 (81.3, 95.2)